Table 2 Change in GFRe in response to FONT study intervention: Rosiglitazone versus adalimumab
Patient # | Rosiglitazone | Adalimumab | ||||
|---|---|---|---|---|---|---|
Follow-up interval (months) | ΔGFRe slope* | Follow-up interval (months) | ΔGFRe slope* | |||
Pre | Post | Pre | Post | |||
1 | 12 | 21 | 7.91 | 6 | 10 | -0.39 |
2 | 25 | 19 | 0.46 | 16 | 6 | 4.04 |
3 | 7 | 26 | -5.73 | 14 | 18 | -2.28 |
4 | 23 | 20 | 0.91 | 11 | 20 | 0.12 |
5 | 12 | 20 | -4.01 | 50 | 17 | 6.35 |
6 | 12 | 9 | 1.96 | 6 | 17 | 10.36 |
7 | 14 | 17 | 6.42 | 23 | 16 | 0 |
8 | 12 | 13 | 4.23 | 18 | 16 | 1.33 |
9 | 24 | 25 | 3.58 | 32 | 7 | 0.62 |
10 | 25 | 20 | -1.65 | 23 | 14 | -11.69 |
11 | 20 | 7 | 3.23 | |||
Mean ± SD | 16.8 ± 6.4 | 18.0 ± 6.0 | 1.72 ± 4.10 | 20 ± 13 | 14 ± 5 | 0.84 ± 5.78 |